Carcinoid Tumors
July 2023 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Authors:Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL
Institution:Medical Oncology Department, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Medical Oncology Department, Institut Catala d'Oncologia (ICO) - Badalona, Hospital Germans Trias i Pujol, Badalona, Spain.
Journal:Nat Commun. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5.

2:Growth Rates of Pulmonary Carcinoid Tumors and Hamartomas.
Authors:Ryan JW, Hammer MM
Institution:From the Brigham and Women's Hospital, Boston MA.
Journal:J Comput Assist Tomogr. 2023 May-Jun 01;47(3):396-401. doi: 10.1097/RCT.0000000000001413. Epub 2023 Jan 14.

3:Lung neuroendocrine neoplasms: a single centre surgical series and analysis of staging.
Authors:Davies RA, Alam NZ, Wright GM
Institution:Department of Cardiothoracic Surgery, St Vincent's Hospital, Melbourne, Victoria, Australia.
Journal:ANZ J Surg. 2023 Jun;93(6):1543-1550. doi: 10.1111/ans.18493. Epub 2023 Apr 27.

4:Pancreatic metastases in patients with neuroendocrine neoplasms: A multi-centre cohort study.
Authors:Tsoli M, Daskalakis K, Wedin M, Angelousi A, Povlsen S, Srirajaskanthan R, Giovos G, Weickert MO, Kogut A, Kos-Kudla B, Oleinikov K, Grozinsky-Glasberg S, Kaltsas G
Institution:Neuroendocrine Tumour Unit, ENETS Centre of Excellence, First Department of Propaedeutic and Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Journal:J Neuroendocrinol. 2023 Apr;35(4):e13269. doi: 10.1111/jne.13269.

5:Nomograms for predicting survival in patients with gastric carcinoid or neuroendocrine carcinoma based on the SEER database.
Authors:Shi H, Sun SY, Liu SS, Liu XN, He YS, Peng Q
Institution:Department of Gastroenterology, The Central Hospital of Shaoyang, University of South China, Shaoyang, Hunan Province, China.
Journal:Eur Rev Med Pharmacol Sci. 2023 Apr;27(7):3071-3081. doi: 10.26355/eurrev_202304_31941.

6:Outcome of carcinoid heart syndrome in patients enrolled in the SwissNet cohort.
Authors:Grundmann E, Curioni-Fontecedro A, Christ E, Siebenhüner AR
Institution:Department of Medical Oncology and Hematology, University Hospital Zurich and University Zurich, Ramistrasse 100, Zurich, CH-8091, Switzerland.
Journal:BMC Cancer. 2023 Apr 13;23(1):338. doi: 10.1186/s12885-023-10739-z.

7:Everolimus in combination with octreotide LAR in thymic atypical carcinoid.
Authors:Sakane T, Nakano T, Hagui E, Haneda H, Okuda K
Institution:Department of Thoracic Surgery, Nagoya City University West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya, 462-8508, Japan.; Department of Thoracic and Pediatric Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Journal:Thorac Cancer. 2023 May;14(15):1404-1407. doi: 10.1111/1759-7714.14887. Epub 2023 Apr 10.

8:Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
Authors:Cheng Y, Anthony L, Delcher C, Moga DC, Chauhan A, Huang B, Adams V
Institution:Department of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, KY, USA.
Journal:Oncologist. 2023 Jun 2;28(6):479-485. doi: 10.1093/oncolo/oyad057.

9:Lobar versus sublobar resection for atypical lung carcinoid: An analysis from the National Cancer Database.
Authors:Ernani V, Appiah AK, Rodriguez D, Kusne Y, Beamer SE, Ravanbakhsh S, Jaroszewski D, Reck Dos Santos P, Sio TT, Yu N, Yang P, Schild S, D'Cunha J
Institution:Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA.; Division of Thoracic Surgery, Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, Arizona, USA.
Journal:Cancer. 2023 Mar 15;129(6):860-866. doi: 10.1002/cncr.34614. Epub 2022 Dec 22.

10:Large-cell Neuroendocrine Carcinoma of the Lung with Carcinoid Syndrome.
Authors:Yamamoto M, Ito R, Tsujibata A, Morita H, Yoneda T, Matano Y, Higashikata T
Institution:Department of Internal Medicine, Komatsu Municipal Hospital, Japan.
Journal:Intern Med. 2023 May 15;62(10):1557-1563. doi: 10.2169/internalmedicine.0099-22. Epub 2022 Oct 5.

11:Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
Authors:Ferolla P, Berruti A, Spada F, Brizzi MP, Ibrahim T, Marconcini R, Giuffrida D, Amoroso V, La Salvia A, Vaccaro V, Faggiano A, Colao A, Volante M, Ghizzoni S, Mazzanti P, Houchard A, Fazio N
Institution:Multidisciplinary NET Center, Umbria Regional Cancer Network, Perugia, Italy.; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, IEO, Milan, Italy.
Journal:Neuroendocrinology. 2023;113(3):332-342. doi: 10.1159/000526811. Epub 2022 Aug 31.

12:Fatigue and quality of life in patients with neuroendocrine neoplasia.
Authors:Hummelshøj NE, Gronbaek H, Bager P, Tabaksblat E, Dam G
Institution:Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Journal:Scand J Gastroenterol. 2023 Jan;58(1):45-53. doi: 10.1080/00365521.2022.2100228. Epub 2022 Jul 18.

13:Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.
Authors:Zhang S, Chen J, Zhang R, Xu L, Wang Y, Yuan Z, Hou X, Feng J
Institution:Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, 20 Xi-Si Road, Nantong, 226001, Jiangsu, China.
Journal:J Cancer Res Clin Oncol. 2023 Mar;149(3):1063-1077. doi: 10.1007/s00432-022-03970-x. Epub 2022 Mar 6.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 25% Discount

Medifocus Guidebook on Carcinoid Tumors

Updated: January 10, 2023
166 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $39.95
  • Less 25% Discount = - $10.00
  • Discounted Price = $29.95(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $26.60
  • Less 25% Discount = - $6.65
  • Discounted Price = $19.95

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 25% discount when you order your Guidebook by phone.

To receive your 25% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: January 5, 2024

What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
Newcastle, England

"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
Nanaimo, British Columbia

"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
Agoura Hills, California

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.